MedTrace Logo

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

NCT01499368 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 495

Last updated 2025-01-15

Study results available
· View outcomes & findings →

Summary

To evaluate the healing rate and safety of Lafutidine in erosive esophagitis

Conditions

  • Erosive Esophagitis

Interventions

DRUG

Lafutidine

Lafutidine 20mg/day

DRUG

Famotidine

Famotidine 40mg/day

DRUG

Omeprazole

Omeprazole 20mg/day

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Sang Woo Lee · Korea University Ansan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-11-30
Completion
2012-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01499368 on ClinicalTrials.gov